(Q40592751)

English

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

scientific article published on May 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours (English)

1 reference

10.1016/S0959-8049(03)00057-1

https://api.crossref.org/works/10.1016/S0959-8049(03)00057-1

26 December 2023

0 references

1 reference

10.1016/S0959-8049(03)00057-1

https://api.crossref.org/works/10.1016/S0959-8049(03)00057-1

26 December 2023

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Eskens FA

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

F. A L M. Eskens

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

H. Dumez

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

R. Hoekstra

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

A. Perschl

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

C. Brindley

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

S. Böttcher

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

W. Wynendaele

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

J. Drevs

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

J. Verweij

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

A. T. van Oosterom

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706360

26 December 2023

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12706360

26 December 2023

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0959804903000571?httpAccept=text/xml

1 reference

10.1016/S0959-8049(03)00057-1

https://api.crossref.org/works/10.1016/S0959-8049(03)00057-1

26 December 2023

https://api.elsevier.com/content/article/PII:S0959804903000571?httpAccept=text/plain

1 reference

10.1016/S0959-8049(03)00057-1

https://api.crossref.org/works/10.1016/S0959-8049(03)00057-1

26 December 2023

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

917-926

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential expression of alphav integrins in K1735 melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients

15

1 reference

10.1016/S0959-8049(03)00057-1

https://api.crossref.org/works/10.1016/S0959-8049(03)00057-1

26 December 2023

Identifiers

10.1016/S0959-8049(03)00057-1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40592751&oldid=2143674690"